{"slug":"ara-290-gabapentin-lyrica","verification":{"valid":true,"entries":19,"head":"9f06ebd835132141acd1d62e4d3d8f2b45721deee607d897a9549b3a87f2dd73"},"energy":{"passes":19,"tokens_in":16847,"tokens_out":1999,"tokens_total":18846,"cost_usd":0,"models":{"grok/grok-4.3":2,"grok-4.3":5,"system/audit-repair":7,"kimi/moonshot-v1-8k":2,"gemini/gemini-2.5-flash":1,"repair":1,"owner":1},"head":"9f06ebd835132141acd1d62e4d3d8f2b45721deee607d897a9549b3a87f2dd73"},"provenance":[{"ts":"2026-06-29T08:53:08.999Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"PEPTIDE DEFINITIONS (use for mechanism accuracy; no medical claims):\nBPC-157 — Body Protection Compound. Derived from gastric juice protein. Builds new blood vessels into damaged tissue locally. 100+ animal/cell studies (tendon, gut, muscle, bone, nerve).\nTB-500 — Synthetic Thymosin Beta-4. Moves repair cells to damage; clears stuck inflammation systemically. Production drops ~60% by age 60.\nARA-290 — Nerve repair peptide with human clinical trial data. Regrows damaged nerves; does not mask nerve pain.\nSemax — Brain peptide; upregulates BDNF for neuroprotection and cognitive recovery.\nSelank — Anxiolytic peptide; reduces anxiety without sedation or addiction (non-benzodiazepine pathway).\nPT-141 — Sexual function; brain-level arousal signaling (FDA-approved mechanism as Vyleesi).\nDSIP — Delta Sleep Inducing Peptide; natural deep sleep without Ambien-class hangover.\nKPV — Gut-specific anti-inflammatory; calms gut lining without systemic immune suppression.\nGHK-Cu — Tissue remodeling; builds collagen scaffolding. Production drops 60-80% with age.\nThymosin Alpha-1 — Immune modulation; supports immune function without suppressing it.\n\nWrite a data-first, evidence-graded article: ARA-290 vs Gabapentin and Lyrica\n\nAudience: 15M on gabapentin. The problem: gabapentin dampens nerve signals and masks pain; nerve damage remains; side effects include dizziness, weight gain, cognitive fog. Why ARA-290 maps: repairs the nerve itself instead of masking pain. Novelty: 9/10.\n\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate rat studies from human trials from user reports. No medical claims or treatment promises. Use repair-vs-suppression framing where relevant. register: source_ledger.","response":"{\n  \"slug\": \"ara-290-vs-gabapentin-and-lyrica\",\n  \"title\": \"ARA-290 vs Gabapentin and Lyrica: Human Trial Data on Nerve Repair Versus Signal Suppression\",\n  \"body\": \"## Overview of Mechanisms\\n\\nGabapentin and pregabalin (Lyrica) bind to the α2δ subunit of voltage-gated calcium channels, reducing neurotransmitter release and dampening nerve signal transmission (human mechanistic data from reviews). No human data demonstrate reversal of underlying nerve damage.\\n\\nARA-290 is an 11-amino-acid peptide derived from erythropoietin that selectively activates the innate repair receptor (IRR). Human clinical trials report increased corneal nerve fiber density and symptom improvement in small fiber neuropathy.\\n\\n## Human Clinical Data on ARA-290\\n\\nIn a randomized double-blind placebo-controlled trial of 49 adults with type 2 diabetes and painful neuropathy, daily subcutaneous ARA-290 4 mg for 28 days improved neuropathic symptoms on PainDetect questionnaire versus placebo (human trial data). Corneal nerve fiber regeneration was observed in sarcoidosis-associated small fiber neuropathy trials (human data).\\n\\nNo human data exist on direct head-to-head comparison of ARA-290 versus gabapentin or pregabalin.\\n\\n## Side Effect Profiles\\n\\nGabapentin and pregabalin are associated with dizziness, somnolence, weight gain, and cognitive effects in human clinical use (review data). ARA-290 trials reported no relevant adverse events in the studied populations (human trial data).\\n\\n## Repair Versus Suppression Framing\\n\\nGabapentinoids reduce pain signaling without evidence of nerve regrowth in human studies. ARA-290 human trials link symptom changes to measurable increases in nerve fiber density, consistent with repair pathway activation rather than signal masking.\\n\\n## Evidence Limitations\\n\\nAll direct efficacy comparisons between ARA-290 and gabapentinoids remain speculative due to absence of comparative human trials. Preclinical data exist for ARA-290 nerve repair but are separ","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"e96d3bd8c91b1e6f2180c7d66fc3a6cf33c4003ddc6fb4aee5e173ea2bf5e137"},{"ts":"2026-06-29T10:34:22.359Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-290-gabapentin-lyrica","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"e96d3bd8c91b1e6f2180c7d66fc3a6cf33c4003ddc6fb4aee5e173ea2bf5e137","hash":"89e2c3ca6fa2af5b3d9332f6450649460fbad0833626528037d25b824040410a"},{"ts":"2026-06-29T10:34:43.951Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-290-gabapentin-lyrica","response":"8 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"89e2c3ca6fa2af5b3d9332f6450649460fbad0833626528037d25b824040410a","hash":"9f3ded585ca7c0a8cd4bfbbcfbc13c9d6f97c11be6130576825f06d0588feb79"},{"ts":"2026-06-29T10:35:01.874Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-290-gabapentin-lyrica","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9f3ded585ca7c0a8cd4bfbbcfbc13c9d6f97c11be6130576825f06d0588feb79","hash":"dbddddf11040755e693160781472a773b2b32f63a338ec89ff970ef6c23d842b"},{"ts":"2026-06-29T10:35:30.366Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-290-gabapentin-lyrica","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"dbddddf11040755e693160781472a773b2b32f63a338ec89ff970ef6c23d842b","hash":"b126870883c88be19c78f841427ce6818a54249a9d4fa756c4412726704a6829"},{"ts":"2026-06-29T12:48:09.845Z","model":"system/audit-repair","action":"repair","prompt":"","input":"ara-290-gabapentin-lyrica","response":"{\"materialized\":0,\"before\":[\"missing constitution slots: what_is_known, what_is_unknown, disclaimer\"],\"after\":[\"missing constitution slots: what_is_known, what_is_unknown, disclaimer\"]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"b126870883c88be19c78f841427ce6818a54249a9d4fa756c4412726704a6829","hash":"f64e558764e49fd046bfba3db7b3bf8a055b9539104f5ac78f32c6ec5414c6af"},{"ts":"2026-06-29T12:48:10.510Z","model":"system/audit-repair","action":"claim","prompt":"","input":"ara-290-gabapentin-lyrica c26","response":"Per this ledger on ARA-290 vs Gabapentin and Lyrica: Human Trial Data on Nerve Repair Versus Signal Suppression: 13 scientific and 9 anecdotal sources are catalogued; 5 preclinical claim(s) summarize animal/cell literature in-catalogue.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f64e558764e49fd046bfba3db7b3bf8a055b9539104f5ac78f32c6ec5414c6af","hash":"4e82bf6ef6ef89588504da7273b3d4535ca414c3b7f06f9413cf2de93c0586b6"},{"ts":"2026-06-29T12:48:10.551Z","model":"system/audit-repair","action":"claim","prompt":"","input":"ara-290-gabapentin-lyrica c27","response":"Not established in this ledger: large randomized human trials for common marketed uses; long-term human safety beyond small pilots; condition-specific efficacy where only anecdotal or preclinical sources exist (explicit gaps remain in question graph).","tokens_in":0,"tokens_out":0,"cost":0,"prev":"4e82bf6ef6ef89588504da7273b3d4535ca414c3b7f06f9413cf2de93c0586b6","hash":"6de65ee9391fcb563340d35729ec92457e694908dff0952f5e2eec5527de90ac"},{"ts":"2026-06-29T12:48:10.598Z","model":"system/audit-repair","action":"claim","prompt":"","input":"ara-290-gabapentin-lyrica c28","response":"Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"6de65ee9391fcb563340d35729ec92457e694908dff0952f5e2eec5527de90ac","hash":"e84b72d1ad48230f0b4343fe53d7b7f05ea2abd59e1fd446e7cea6d996dda6b8"},{"ts":"2026-06-29T12:48:11.190Z","model":"system/audit-repair","action":"repair","prompt":"","input":"ara-290-gabapentin-lyrica","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"e84b72d1ad48230f0b4343fe53d7b7f05ea2abd59e1fd446e7cea6d996dda6b8","hash":"38b4872587e449b7a10d3890bfbd2e3451c612cd9ab3d0defebe7c4cbbd7e5cd"},{"ts":"2026-06-29T13:23:23.483Z","model":"kimi/moonshot-v1-8k","action":"collaborate","prompt":"","input":"ara-290-gabapentin-lyrica","response":"As Kimi, I am adding explicit gaps to the ledger and naming who claims what from anecdotes where missing, which are my responsibilities as collaborator #1 on the miscsubjects peptide evidence ledger. I am not Grok, who is presumably responsible for other aspects of the ledger.","tokens_in":3259,"tokens_out":314,"cost":0,"prev":"38b4872587e449b7a10d3890bfbd2e3451c612cd9ab3d0defebe7c4cbbd7e5cd","hash":"0e503f4fcfee9cc8dac580ca7f28ae381c372a3176d31e8d1bf5a44e134ffb7d"},{"ts":"2026-06-29T13:24:01.198Z","model":"system/audit-repair","action":"repair","prompt":"","input":"ara-290-gabapentin-lyrica","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"0e503f4fcfee9cc8dac580ca7f28ae381c372a3176d31e8d1bf5a44e134ffb7d","hash":"0725c443654cf7288e92dfd1d5d1111c6e0bac9b4396c34288095ffb19a3d885"},{"ts":"2026-06-29T13:24:02.330Z","model":"system/audit-repair","action":"repair","prompt":"","input":"ara-290-gabapentin-lyrica","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"0725c443654cf7288e92dfd1d5d1111c6e0bac9b4396c34288095ffb19a3d885","hash":"61b2197ded6833eef03f20ab21afa9980ebb52b8c4b665da6cf9d35a5e7dd4d2"},{"ts":"2026-06-29T13:24:24.347Z","model":"kimi/moonshot-v1-8k","action":"collaborate","prompt":"","input":"ara-290-gabapentin-lyrica","response":"I am adding explicit gaps in the ledger's knowledge and naming anecdotal claimants as instructed, as I am not Grok and am capable of identifying and filling in these gaps.","tokens_in":3259,"tokens_out":332,"cost":0,"prev":"61b2197ded6833eef03f20ab21afa9980ebb52b8c4b665da6cf9d35a5e7dd4d2","hash":"bcb8ada9cbb13f6944da9b07249fc69cd7e62975bcca85a7a246e8c0786db1e3"},{"ts":"2026-06-29T14:51:52.993Z","model":"gemini/gemini-2.5-flash","action":"collaborate","prompt":"","input":"ara-290-gabapentin-lyrica","response":"As Gemini, I've added three tier-honest claims to address gaps in the ledger, focusing on what remains unknown about long-term comparative outcomes and introducing specific claims from existing medical and review sources about ARA-290 and its comparators. I am not Grok, and my additions are based strictly on the provided topology and instructions.","tokens_in":2914,"tokens_out":434,"cost":0,"prev":"bcb8ada9cbb13f6944da9b07249fc69cd7e62975bcca85a7a246e8c0786db1e3","hash":"77b7d854fd0a24589c2822e8ebd4399012c53a267af2a9b8d06b7e36fa0ad6da"},{"ts":"2026-06-29T14:52:48.416Z","model":"grok/grok-4.3","action":"synthesize_body","prompt":"","input":"ara-290-gabapentin-lyrica","response":"## Regeneration vs degeneration — where this fits\nNerves can break down after injury or disease. When breakdown exceeds repair, numbness, pain, and loss of function persist. Gabapentin and pregabalin bind calcium channels and lower pain signal strength. ARA-290 research examines whether small nerve fibers can regrow after damage.\n\n## What it is\nARA-290 is a peptide studied in human trials for small-fiber neuropathy and related nerve conditions. Gabapentin and pregabalin (Lyrica) are drugs that act on nerve signaling to reduce pain perception. The comparison centers on repair versus signal suppression.\n\n## How it works\nGabapentinoids attach to the α2δ subunit of calcium channels. This reduces neurotransmitter release and dampens pain signals. ARA-290 is described as activating the innate repair receptor. One 2025 paper states it inhibits NLRP3 inflammasome activation after nerve injury (source s10). Human trial reports note increased corneal nerve fiber density after 28 days of use (source s2).\n\n## Why it would work (logic chain)\nIf inflammation blocks repair, lowering that inflammation could allow regrowth. If the innate repair receptor promotes healing signals, activating it could shift tissue from damage mode to repair mode. If corneal nerve fibers increase, similar changes might occur in other small-fiber areas. Signal suppression alone does not rebuild tissue; repair pathways would need to be active for structural change.\n\n## Why people take it\nPeople seek options when standard drugs do not fully control symptoms or when they want to address underlying nerve changes. Some report using ARA-290 while lowering gabapentin intake. Others try it after side effects from pregabalin or gabapentin.\n\n## How many people take it\nThe ledger contains seven Reddit posts and two other anecdote sources. No total population count exists in the sources. Clinical trial enrollment numbers are not reported here.\n\n## Evidence inventory\n13 studies catalogued. 3 human claims. 5 preclinic","tokens_in":7415,"tokens_out":919,"cost":0,"prev":"77b7d854fd0a24589c2822e8ebd4399012c53a267af2a9b8d06b7e36fa0ad6da","hash":"397395bd5938d0d6b0a94f7c232f4bff3b3ccdb31bd3ede82268a453b6ccc227"},{"ts":"2026-06-29T17:59:23.124Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-290-gabapentin-lyrica","response":"7 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"397395bd5938d0d6b0a94f7c232f4bff3b3ccdb31bd3ede82268a453b6ccc227","hash":"5bdb4261feba5cbabc8eddd63a6851ee49826ef8fe0c41ae73e484160ee0c285"},{"ts":"2026-06-29T19:41:05.122Z","model":"repair","action":"repair","prompt":"","input":"ara-290-gabapentin-lyrica","response":"{\"materialized\":0,\"before\":[],\"after\":[],\"focus_stats\":{\"roles_assigned\":0,\"excluded_sources\":0,\"commercial_sources\":0,\"cut_claims\":0,\"core\":2,\"cycle\":3,\"adjacent\":17}}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"5bdb4261feba5cbabc8eddd63a6851ee49826ef8fe0c41ae73e484160ee0c285","hash":"e80f1b2fc46679673a55038011423cabaed9f5627553de446b5a18ef0796eedf"},{"ts":"2026-07-17T02:38:11.170Z","model":"owner","action":"voxel_divide","prompt":"","input":"ara-290-gabapentin-lyrica","response":"24 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"e80f1b2fc46679673a55038011423cabaed9f5627553de446b5a18ef0796eedf","hash":"9f06ebd835132141acd1d62e4d3d8f2b45721deee607d897a9549b3a87f2dd73"}]}